Lv51
1590 积分 2023-09-25 加入
Sunvozertinib: First Approval
27天前
已完结
The present and future of bispecific antibodies for cancer therapy
1个月前
已完结
Targeting KRAS in cancer
1个月前
已完结
Targeting cancer with small molecule pan-KRAS degraders
1个月前
已完结
Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study
1个月前
已完结
Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC
1个月前
已完结
Overcoming therapy resistance in EGFR-mutant lung cancer
1个月前
已完结
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
1个月前
已完结
A phase 2 trial combining afatinib with cetuximab in patients with EGFR exon 20 insertion–positive non–small cell lung cancer
2个月前
已完结
ErbB receptors and signaling pathways in cancer
2个月前
已完结
Phase 1/2a study of AZD5305, a novel poly(adenosine diphosphate ribose) polymerase (PARP) 1-selective inhibitor in combination with new hormonal agents (NHAs) in patients (pts) with metastatic prostate cancer (mPC)
10个月前
已采纳
Phase 1/2a study of AZD5305, a novel poly(adenosine diphosphate ribose) polymerase (PARP) 1-selective inhibitor in combination with new hormonal agents (NHAs) in patients (pts) with metastatic prostate cancer (mPC)
10个月前
已采纳
皖公网安备34019202002308
